Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics has successfully closed its public offering, raising $3.05 million in gross proceeds through the sale of 762,500 common shares. The company plans to use the funds for working capital, general corporate purposes, and advancing its business objectives, marking an essential step in strengthening its financial position in the biotechnology sector.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
YTD Price Performance: -50.86%
Average Trading Volume: 7,536
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$17.59M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.